P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
Aim To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
[引用][C] P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
D Aggarwal, K Bhatia… - European heart …, 2022 - scholarlyworks.beaumont.org
METHODS AND RESULTS: Medline, Embase, and Cochrane Central databases were
searched to identify randomized trials comparing monotherapy with a P2Y CONCLUSION …
searched to identify randomized trials comparing monotherapy with a P2Y CONCLUSION …
P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials.
D Aggarwal, K Bhatia, ZS Chunawala… - … Heart Journal Open, 2022 - europepmc.org
Aim To compare the efficacy and safety of P2Y 12 inhibitor or aspirin monotherapy for
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
[HTML][HTML] P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
D Aggarwal, K Bhatia, ZS Chunawala… - … Heart Journal Open, 2022 - ncbi.nlm.nih.gov
Aim To compare the efficacy and safety of P2Y 12 inhibitor or aspirin monotherapy for
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
D Aggarwal, K Bhatia… - … heart journal open, 2022 - pubmed.ncbi.nlm.nih.gov
Aim To compare the efficacy and safety of P2Y 12 inhibitor or aspirin monotherapy for
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
[PDF][PDF] P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
D Aggarwal, K Bhatia, ZS Chunawala… - … Heart Journal Open, 2022 - academic.oup.com
Aim To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …